Agios Pharmaceuticals (NASDAQ:AGIO) saw its stock rise 12% on Tuesday following an update that indicated forward movement toward a potential U.S. accelerated approval for mitapivat in sickle cell disease. The announcement summarized outcomes from a pre-supplemental New Drug Application meeting with the U.S. Food and Drug Administration.
At that meeting, the FDA advised Agios to submit a proposal for a confirmatory clinical trial to support an accelerated approval pathway for mitapivat, which is an oral pyruvate kinase activator. Under the accelerated approval framework, a drug that addresses a serious medical need may be made available sooner, but a confirmatory clinical trial is required to convert accelerated approval into traditional approval.
Agios has already filed the proposed design for the required confirmatory study with the FDA for review. According to the company, the proposal introduces a primary endpoint that differs from those used in the RISE UP clinical program and reflects analyses of RISE UP results plus input from discussions with the FDA. Agios also indicated it plans to submit a supplemental New Drug Application for mitapivat in sickle cell disease in the coming months and is continuing to work with the regulator to align on the confirmatory trial that will be needed for full-review submission.
On the company guidance front, Agios said that based on its current planning assumptions, the proposed confirmatory clinical trial is not expected to alter the operating expense guidance it previously issued. That guidance remains approximately flat compared with 2025.
The pre-supplemental meeting centered on presentation of data from the mitapivat RISE UP clinical program in sickle cell disease, which includes both Phase 2 and Phase 3 trials. The company described its meeting outcomes as a step toward defining the regulatory pathway and the confirmatory study necessary under an accelerated approval scenario.
Investors reacted to the regulatory update with a notable rise in the company's share price on Tuesday, reflecting market recognition of the development while the confirmatory trial design and formal FDA review process continue.
Key points
- Agios stock rose 12% after a pre-supplemental NDA meeting with the FDA signaled a path for accelerated approval of mitapivat in sickle cell disease.
- The FDA recommended submission of a confirmatory clinical trial proposal; Agios has submitted that proposal and plans to file a supplemental NDA in the coming months.
- Company guidance on operating expenses is expected to remain approximately flat versus 2025, based on current planning assumptions.
Risks and uncertainties
- A confirmatory clinical trial is required to convert any accelerated approval to traditional approval, and the outcome and timeline of that trial remain uncertain.
- The FDA must review and accept the submitted confirmatory trial proposal and any supplemental NDA, so regulatory alignment is not yet final.
- Although Agios currently expects the proposed trial not to change its operating expense guidance, changes to trial design or timing could affect future expense assumptions.